Feedback / Questions
tarextumab (OMP-59R5) - MorphoSys, Mereo Biopharma, GSK
MorphoSys: Leerink Partners Annual Emerging Biotech Conference
(Morphosys)
-
Mar 13, 2016 -
Anticipated data from P2 ALPINE trial (NCT01647828) for pancreatic cancer in 2016
Anticipated P2 data
•
Oncology • Pancreatic Cancer
https://www.morphosys.com/sites/default/files/presentations/160308_mor-company_update_web.pdf
Mar 13, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.